Moderna and merck announce mrna-4157 (v940) in combination with keytruda(r) (pembrolizumab) demonstrated a statistically significant and clinically meaningful improvement in distant metastasis-free survival in patients with high-risk stage iii/iv melanoma following complete resection versus keytruda

Mrna-4157 (v940) in combination with keytruda reduced the risk of distant metastasis or death by 65% (hr=0.347 [95% ci, 0.145-0.828]); one-sided p value=0.0063) compared to keytruda alone the dmfs results, a key secondary endpoint of the phase 2b keynote-942 study, will be presented at the 2023 american society of clinical oncology (asco) annual meeting companies plan to initiate a phase 3 study in the adjuvant setting in patients with high-risk melanoma in 2023, and rapidly expand to additional tumor types, including non-small cell lung cancer cambridge, ma and rahway, nj / accesswire / june 5, 2023 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, and merck (nyse:mrk), known as msd outside of the united states and canada, today announced distant metastasis-free survival (dmfs) results from the phase 2b randomized keynote-942/mrna-4157-p201 study, a clinical trial evaluating mrna-4157 (v940), an investigational individualized neoantigen therapy (int), in combination with keytruda, merck's anti-pd-1 therapy, in patients with resected high-risk melanoma (stage iii/iv). in the overall intention-to-treat (itt) population, adjuvant treatment with mrna-4157 (v940) in combination with keytruda demonstrated a statistically significant and clinically meaningful improvement in dmfs, a key secondary endpoint of the study, compared with keytruda alone and reduced the risk of developing distant metastasis or death by 65% (hr=0.347 [95% ci, 0.145-0.828]); one-sided p value=0.0063).
MRNA Ratings Summary
MRNA Quant Ranking